Karius, the leading U.S. infectious disease genomics company, announced today that the new version of its proprietary KariusTM Test can now quantify the abundance of pathogens detected. The test uses next-generation sequencing of microbial cell-free DNA (cfDNA) to identify over 1,000 pathogens from a single blood sample. Results are typically delivered the next day. Karius is announcing its latest advances at the first annual HLTH “The Future of Healthcare” conference and is making the test immediately orderable to physicians nationwide. Reade More
